Johnson & Johnson (JNJ) Morgan Stanley 24th Annual Global Healthcare Conference summary

Strategic growth and portfolio focus

• Portfolio now centers on oncology, immunology, neuroscience, vision, surgery, and cardiovascular, driving a new cycle of accelerated growth since 2023.

• 2026 guidance targets 6.5% adjusted operational sales growth and 7.3% adjusted EPS growth, with revenue surpassing $100 billion for the first time.

• Double-digit growth is projected by the end of the decade, with 2027 expected to outperform 2026.

• Upcoming enterprise business review will provide more detail on growth durability and pipeline strength beyond 2030.

Pipeline and innovation highlights

• Pipeline includes 12 phase III molecules and 10 in-market medicines early in their lifecycle, supporting robust growth.

• Recent acquisitions (Halda Therapeutics, Firefly Bio, Sail) add platforms in induced proximity, degrader-antibody conjugates, and in vivo CAR-T.

• RIPTAC platform targets androgen receptors in prostate cancer, showing strong early efficacy and tolerability, with expansion into breast cancer and immunology.

• Firefly’s pan-KRAS degrader aims to address the most common genetic mutation in human cancers.

• In vivo CAR-T platforms (viral and non-viral) are entering the clinic, with applications in oncology and immunology.

Capital allocation and business development

• Strong balance sheet with AAA credit rating and robust cash flow supports new product launches and pipeline investment.

• Capital priorities: fund new launches, resource pipeline (especially late-stage), pursue early-stage external opportunities, and maintain dividend growth.

• M&A is focused on fortifying long-term growth beyond the decade, not required for current double-digit growth targets.